Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2004 2
2005 3
2006 1
2007 5
2008 2
2010 1
2011 9
2012 10
2013 5
2014 6
2015 6
2016 8
2017 7
2018 7
2019 9
2020 3
2021 5
2022 7
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

85 results

Results by year

Filters applied: . Clear all
Page 1
Fibroblast growth factor 23, klotho and heparin.
Thomas SM, Li Q, Faul C. Thomas SM, et al. Among authors: faul c. Curr Opin Nephrol Hypertens. 2023 Jul 1;32(4):313-323. doi: 10.1097/MNH.0000000000000895. Epub 2023 May 4. Curr Opin Nephrol Hypertens. 2023. PMID: 37195242 Free PMC article. Review.
Soluble α-klotho and heparin modulate the pathologic cardiac actions of fibroblast growth factor 23 in chronic kidney disease.
Yanucil C, Kentrup D, Campos I, Czaya B, Heitman K, Westbrook D, Osis G, Grabner A, Wende AR, Vallejo J, Wacker MJ, Navarro-Garcia JA, Ruiz-Hurtado G, Zhang F, Song Y, Linhardt RJ, White K, Kapiloff MS, Faul C. Yanucil C, et al. Among authors: faul c. Kidney Int. 2022 Aug;102(2):261-279. doi: 10.1016/j.kint.2022.03.028. Epub 2022 May 2. Kidney Int. 2022. PMID: 35513125 Free PMC article.
The bone at the intersection of kidney and heart disease.
Campos I, Faul C. Campos I, et al. Among authors: faul c. Trends Pharmacol Sci. 2022 Feb;43(2):84-86. doi: 10.1016/j.tips.2021.11.014. Epub 2021 Dec 2. Trends Pharmacol Sci. 2022. PMID: 34865884
Discontinuation versus continuation of renin-angiotensin-system inhibitors in COVID-19 (ACEI-COVID): a prospective, parallel group, randomised, controlled, open-label trial.
Bauer A, Schreinlechner M, Sappler N, Dolejsi T, Tilg H, Aulinger BA, Weiss G, Bellmann-Weiler R, Adolf C, Wolf D, Pirklbauer M, Graziadei I, Gänzer H, von Bary C, May AE, Wöll E, von Scheidt W, Rassaf T, Duerschmied D, Brenner C, Kääb S, Metzler B, Joannidis M, Kain HU, Kaiser N, Schwinger R, Witzenbichler B, Alber H, Straube F, Hartmann N, Achenbach S, von Bergwelt-Baildon M, von Stülpnagel L, Schoenherr S, Forer L, Embacher-Aichhorn S, Mansmann U, Rizas KD, Massberg S; ACEI-COVID investigators. Bauer A, et al. Lancet Respir Med. 2021 Aug;9(8):863-872. doi: 10.1016/S2213-2600(21)00214-9. Epub 2021 Jun 11. Lancet Respir Med. 2021. PMID: 34126053 Free PMC article. Clinical Trial.
85 results